Wells Fargo & Co. upgraded C R Bard Inc (NYSE:BCR) to Outperform in a report released today.
- Updated: September 15, 2016
Showing a price of $223.63, C R Bard Inc (NYSE:BCR) traded 3.25% higher on the day. The last stock price close is up 3.45% from the two hundred day moving average, compared to the S&P 500 Index which has decreased -0.01% over the date range. C R Bard Inc has logged a 50-day moving average of $219.98 and two hundred day moving average of $216.50. Trade volume was was up over the average, with 660,450 shares of BCR changing hands over the typical 438,609 shares.
Wells Fargo & Co. has upgraded C R Bard Inc(NYSE:BCR) to Outperform in a report released 9/16/2016.
Previously on 9/15/2016, Evercore ISI released a statement about C R Bard Inc(NYSE:BCR) raised the target price from $0.00 to $235.00 that indicated a possible upside of 0.08%.
Recent Performance Graph:
Also covering C R Bard Inc’s target price, a total of 14 equity analysts have issued a ratings update on C R Bard Inc. The one year target price is $226.21 with two analysts rating the stock a strong buy, four firms rating the company a buy, 14 firms rating the stock a hold, 0 rating the company to underperform, and lastly 0 firms rating the stock as sell.
C R Bard Inc has a 52 week low of $172.21 and a 52 week high of $239.43 with a price-earnings ratio of 52. The company’s market cap is currently $0.0.
Brief Synopsis On C R Bard Inc (NYSE:BCR)
C. R. Bard, Inc. (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities. It operates through the manufacturing and sale of medical devices segment. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease (PVD), end-stage renal disease (ESRD) and heart arrhythmias. Its urology products include basic urology drainage products, fecal and urinary continence products, and urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted grafts and fixation devices for hernia and soft tissue repairs.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.